Amgen bite immunotherapy combined with Revlimid can prevent mm recurrence

At last year's annual meeting of the American Society of Hematology (ash), Amgen's anti BCMA T-cell binding agent achieved a response rate of 70% in early clinical trials for the treatment of multiple myeloma (mm), which attracted wide attention in the industry At the time, Amgen said it was developing a follow-up drug called bite immunotherapy, AMG 701, with a longer half-life, with a view to reducing the burden on patients At this year's ash conference, the Dana Farber Cancer Institute published a preclinical study that they believe demonstrates the promise of AMG 701 in the treatment of mm and the prevention of disease recurrence Dana Farber's team injected mice with myeloma with AMG 701 three times and observed that the tumor disappeared The researchers found that the combination of AMG 701 and Revlimid could not only inhibit tumor growth for a long time, but also prevent recurrence In contrast, mice treated with AMG 701 or Revlimid alone eventually relapsed Bite is a double specific T cell adapter, which has two binding sites One end of the binding site combines with the protein on the cancer cell, and the other end can activate the T cell on the cancer killing T cell to attack the tumor Based on the bite technology platform, Amgen has successfully developed a bite molecule, blinctyo, which can target CD19 and CD3 at the same time The drug has been approved for the treatment of children and adults with recurrent or refractory B-cell acute lymphoblastic leukemia In mm field, the comparison and competition between bite and car-t attract people's attention For example, at this ash annual meeting, Johnson & Johnson announced the preliminary results of stage Ib / II cartitude-1 study of BCMA car-t therapy jnj-4528 in the treatment of relapsed or refractory MM The results showed that during the median follow-up of 6 months, 100% of the patients achieved remission, i.e the total remission rate was 100%, of which 69% achieved complete or better remission, 86% achieved very good partial or better remission At present, there are also many companies in active layout of bite immunotherapy In February this year, Aberdeen signed a $90 million development agreement with teneoone, a subsidiary of teneobio, to develop mm bispecific antibody drugs for BCMA and CD3 In addition to AMG 701, AMG is also testing the efficacy of its bite therapy AMG 420 in mm in a phase 1B / 2 study At the same time, AMG 701 phase 1 study for mm was launched, which will recruit 150 patients and be completed in 2021.